Allogeneic Umbilical Cord Blood
Nervous System Disorder
Explore 31 assets in Nervous System Disorder →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
The Medical Pavilion Bahamas
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05515419CT.gov Allogeneic Cord Blood for Neurological Diseases in Adults | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nervous System Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Allogeneic Umbilical Cord Blood (this asset) | The Medical Pavilion Bahamas | Early P1 | C · 39 |
| Guanfacine | Maimonides Medical Center | P4 | BB |
| Ginkgolide | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BB |
| Brexpiprazole | Otsuka Pharmaceutical Development & Commercialization, Inc. | P3 | BB |
| Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules | Beijing Friendship Hospital | P4 | BB |
| D-Thioctic Acid | Ain Shams University | P4 | BB |
| 3-N-BUTYLPHTHALIDE | Qianfoshan Hospital | P4 | BB |
| Live Combined Bifidobacterium | Beijing Friendship Hospital | P4 | BB |
| Egb 761® | Ipsen | P3 | BB |
+42 more in the Nervous System Disorder cohort
Other indications for Allogeneic Umbilical Cord Blood
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Stroke Disorder | — | P1 | CC · 43 |
| Spinal Cord Injury | — | Early P1 | C · 39 |
| Traumatic Brain Injury | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- GuanfacineMaimonides Medical CenterBB
- GinkgolideSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityBB
- BrexpiprazoleOtsuka Pharmaceutical Development & Commercialization, Inc.BB
- Live Combined Bifidobacterium,Lactobacillus And Enterococcus CapsulesBeijing Friendship HospitalBB
- D-Thioctic AcidAin Shams UniversityBB
Citation
Floatz Terminal. Allogeneic Umbilical Cord Blood in Nervous System Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/allogeneic-umbilical-cord-blood-nervous-system-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →